{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:50:48Z","timestamp":1790754648285,"version":"4.1.0"},"reference-count":28,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Cutaneous T-cell lymphoma (CTCL) constitutes a rare and heterogeneous group of T-cell lymphomas with an unclear pathogenesis. There is emerging evidence that fatty acid binding protein 5 (FABP5) regulates the PPAR\u03b3 signalling pathway through its binding to fatty acids. However, the precise biological role of FABP5 in CTCL remains unclear.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim<\/jats:title>\n<jats:p>To investigate the expression of FABP5 in CTCL and evaluate the effects of targeting FABP5 on the biological behaviors of CTCL tumour cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We performed single-cell transcriptomic analysis to evaluate the expression of FABP5, fatty acid synthase (FASN), and cholesterol regulatory element binding protein (SREBP1) in CTCL patients. FABP5 was knocked down using short interfering RNA (siRNA) lentiviruses, and mRNA expression of FABP5 in CTCL cell lines was quantified by real-time quantitative reverse transcription PCR (RT-qPCR). Cell proliferation and invasion were assessed using CCK-8 and transwell assays, while apoptosis and cell cycle distribution were analysed by flow cytometry. The impact of FABP5 on epithelial-mesenchymal transition (EMT) was investigated via qRT-PCR and Western blot. Intracellular levels of free fatty acids (FFAs), total cholesterol (TC), and triglycerides (TG) were measured with assay kits. The effect of BMS-309403 (a competitive inhibitor of FABP5) on the biological behavior of CTCL cells was also studied.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>FABP5 expression was significantly elevated in CTCL patients and cells compared to healthy controls, and silencing FABP5 inhibited cell proliferation. FABP5 knockout upregulated E-cadherin and downregulated N-cadherin and vascular endothelial growth factor (VEGF), thereby inhibiting EMT. Intracellular levels of FFAs, TC, and TG were also reduced. Bristol-Myers Squibb-309403 (BMS-309403) decreased cell viability, induced apoptosis, and lowered TC, TG, and peroxisome proliferator-activated receptor-\u03b3 (PPAR\u03b3) levels.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Limitations<\/jats:title>\n<jats:p>The study relied solely on in vitro experiments using cell lines. Animal models would strengthen the translational relevance of the findings. In addition, the precise molecular interactions between FABP5 and PPAR\u03b3 signalling in CTCL remain unclear.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our findings suggest that the FABP5\/PPAR\u03b3 axis is a promising therapeutic target in CTCL, with BMS-309403 emerging as a potential agent to reverse lipid metabolic reprogramming in CTCL.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_1624_2024","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:45:12Z","timestamp":1751690712000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FABP5 reprograms lipid metabolism and promotes cutaneous T-cell lymphoma progression via activation of PPAR\u03b3 signalling"],"prefix":"10.25259","volume":"0","author":[{"given":"Shiwen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"10.25259\/IJDVL_1624_2024\/ref-1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"10.25259\/IJDVL_1624_2024\/ref-2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer"},{"key":"10.25259\/IJDVL_1624_2024\/ref-3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"38","author":"Cheng","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"10.25259\/IJDVL_1624_2024\/ref-4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s42003-020-01367-5","article-title":"Fatty-acid-induced FABP5\/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells","volume":"3","author":"Seo","year":"2020","journal-title":"Commun Biol"},{"key":"10.25259\/IJDVL_1624_2024\/ref-5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10555-022-10059-x","article-title":"The adipocyte microenvironment and cancer","volume":"41","author":"Mukherjee","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"10.25259\/IJDVL_1624_2024\/ref-6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1479-7364-5-3-170","article-title":"The human fatty acid-binding protein family: Evolutionary divergences and functions","volume":"5","author":"Smathers","year":"2011","journal-title":"Hum Genomics"},{"key":"10.25259\/IJDVL_1624_2024\/ref-7","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1111\/cas.15883","article-title":"FABP5 regulates lipid metabolism to facilitate pancreatic neuroendocrine neoplasms progression via FASN mediated wnt\/\u03b2-catenin pathway","volume":"114","author":"Lu","year":"2023","journal-title":"Cancer Sci"},{"key":"10.25259\/IJDVL_1624_2024\/ref-8","doi-asserted-by":"publisher","first-page":"103628","DOI":"10.1016\/j.drudis.2023.103628","article-title":"The emerging role of fatty acid binding protein 5 (FABP5) in cancers","volume":"28","author":"George Warren","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.25259\/IJDVL_1624_2024\/ref-9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/1346-8138.15775","article-title":"Mycosis fungoides and Sezary syndrome tumour cells express epidermal fatty acid-binding protein, whose expression decreases with loss of epidermotropism","volume":"48","author":"Takahashi-Shishido","year":"2021","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_1624_2024\/ref-10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jdermsci.2010.07.014","article-title":"Proteomic expression analysis of mycosis fungoides (MF) skin tissues: Overexpressions of SOD2, S100A8 and FABP5 in MF","volume":"60","author":"Liu","year":"2010","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_1624_2024\/ref-11","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.3390\/cancers14184491","article-title":"Concomitant inhibition of FASN and SREBP provides a promising therapy for CTCL","volume":"14","author":"Chi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.25259\/IJDVL_1624_2024\/ref-12","doi-asserted-by":"publisher","first-page":"9237381","DOI":"10.1155\/2020\/9237381","article-title":"Proteomic profiling change and its implies in the early mycosis fungoides (MF) using isobaric tags for relative and absolute quantification (iTRAQ)","volume":"2020","author":"Zhu","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.25259\/IJDVL_1624_2024\/ref-13","doi-asserted-by":"publisher","first-page":"857919","DOI":"10.3389\/fcell.2022.857919","article-title":"The biological functions and regulatory mechanisms of fatty acid binding protein 5 in various diseases","volume":"10","author":"Xu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.25259\/IJDVL_1624_2024\/ref-14","doi-asserted-by":"crossref","first-page":"e81184","DOI":"10.7554\/eLife.81184","article-title":"Targeting the fatty acid binding proteins disrupts multiple myeloma cell cycle progression and MYC signalling","volume":"12","author":"Farrell","year":"2023","journal-title":"Elife"},{"key":"10.25259\/IJDVL_1624_2024\/ref-15","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/sj.bjc.6605007","article-title":"De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy","volume":"100","author":"Mashima","year":"2009","journal-title":"Br J Cancer"},{"key":"10.25259\/IJDVL_1624_2024\/ref-16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"R\u00f6hrig","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.25259\/IJDVL_1624_2024\/ref-17","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.7150\/thno.44868","article-title":"FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.25259\/IJDVL_1624_2024\/ref-18","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1111\/cas.15883","article-title":"FABP5 regulates lipid metabolism to facilitate pancreatic neuroendocrine neoplasms progression via FASN mediated wnt\/\u03b2-catenin pathway","volume":"114","author":"Lu","year":"2023","journal-title":"Cancer Sci"},{"key":"10.25259\/IJDVL_1624_2024\/ref-19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.bbalip.2018.06.010","article-title":"Fatty acid-binding protein 5 (FABP5) promotes lipolysis of lipid droplets, de novo fatty acid (FA) synthesis and activation of nuclear factor-kappa B (NF-\u03baB) signalling in cancer cells","volume":"1863","author":"Senga","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"10.25259\/IJDVL_1624_2024\/ref-20","doi-asserted-by":"crossref","first-page":"31041\u201056","DOI":"10.18632\/oncotarget.16055","article-title":"Inhibitor SBFI26 suppresses the malignant progression of castration\u2010resistant PC3\u2010M cells by competitively binding to oncogenic FABP5","volume":"8","author":"Al-Jameel","year":"2017","journal-title":"Oncotarget"},{"key":"10.25259\/IJDVL_1624_2024\/ref-21","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.18632\/oncotarget.3334","volume":"6","author":"Xia","year":"2015","journal-title":"Oncotarget"},{"key":"10.25259\/IJDVL_1624_2024\/ref-22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/bph.16308","article-title":"Resveratrol, a novel inhibitor of fatty acid binding protein 5, inhibits cervical cancer metastasis by suppressing fatty acid transport into nucleus and downstream pathways","volume":"181","author":"Chen","year":"2024","journal-title":"Br J Pharmacol"},{"key":"10.25259\/IJDVL_1624_2024\/ref-23","doi-asserted-by":"publisher","first-page":"624112","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: Unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.25259\/IJDVL_1624_2024\/ref-24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.18632\/genesandcancer.192","article-title":"Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARgamma","volume":"10","author":"Al-Jameel","year":"2019","journal-title":"Genes Cancer"},{"key":"10.25259\/IJDVL_1624_2024\/ref-25","doi-asserted-by":"crossref","first-page":"9322","DOI":"10.18632\/oncotarget.6975","article-title":"Fatty acid activated PPAR\u03b3 promotes tumourigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter","volume":"7","author":"Forootan","year":"2016","journal-title":"Oncotarget"},{"key":"10.25259\/IJDVL_1624_2024\/ref-26","doi-asserted-by":"crossref","first-page":"1150861","DOI":"10.3389\/fphar.2023.1150861","article-title":"Doxorubicin resistance in breast cancer is mediated via the activation of FABP5\/PPAR\u03b3 and caMKII signalling pathway","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.25259\/IJDVL_1624_2024\/ref-27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.25259\/IJDVL_1624_2024\/ref-28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/fabp5-reprograms-lipid-metabolism-and-promotes-cutaneous-t-cell-lymphoma-progression-via-activation-of-ppar-signalling\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/fabp5-reprograms-lipid-metabolism-and-promotes-cutaneous-t-cell-lymphoma-progression-via-activation-of-ppar-signalling\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:45:26Z","timestamp":1751690726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/fabp5-reprograms-lipid-metabolism-and-promotes-cutaneous-t-cell-lymphoma-progression-via-activation-of-ppar-signalling\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":28,"alternative-id":["10.25259\/IJDVL_1624_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_1624_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"article-number":"1"}}